UNSPSC 51111657: Tezacitabine

This classification denotes a ribonucleotide reductase inhibitor and pyrimidine antagonist with the molecular formula C10H12FN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7607Y95N9S, chemically known as mdl 101,731 but generally known as tezacitabine, which bears US NIH Compound Identifier 6435808. The term TEZACITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 No. 3-4, 2001, List 46). Most nations schedule tezacitabine under HS 29349990 and SITC 51579.

As of Q4 2014, TEZACITABINE remains the US FDA Preferred Term for this commodity. Tezacitabine bears US NLM identifiers UMLS ID C0253087 and NCI Concept Code C1539. SMILES: C1=CN(C(=O)N=C1N)C2C(=CF)C(C(O2)CO)O.

UNSPSC 51111657 Tezacitabine (Commodity) covers procurement of tezacitabine, an investigational nucleoside analog cancer therapeutic. State and local governments do not appear to buy this drug through conventional state and local procurement channels; tezacitabine is a specialized pharmaceutical typically distributed through clinical trial networks, hospital pharmacy systems, or federal research contracts rather than general-market procurement. The code's presence in UNSPSC reflects pharmaceutical taxonomy rather than active state or local contracting demand. No recent state and local opportunities tagged to this code appear in available records.

This code shows no measurable recent activity in state and local procurement markets and is not recommended as a business development target at this time.